Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Laimer, Martin
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Recruiting
2/3
80
Europe, US, RoW
AC-203, Vehicle
TWi Biotechnology, Inc.
Generalized Epidermolysis Bullosa Simplex
08/25
03/26
NCT04908215 / 2021-000214-42: INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Completed
2
19
Europe, RoW
INM-755 (cannabinol) cream, Vehicle Cream
InMed Pharmaceuticals Inc.
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica, Kindler Syndrome
04/23
04/23
CA209-587, NCT04204837 / 2016-002811-16: Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

Recruiting
2
61
Europe
Nivolumab, Nivolumab plus Relatlimab
Salzburger Landeskliniken, Bristol-Myers Squibb
Squamous Cell Carcinoma of the Skin
12/26
12/27
Lang, Roland
CA209-587, NCT04204837 / 2016-002811-16: Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

Recruiting
2
61
Europe
Nivolumab, Nivolumab plus Relatlimab
Salzburger Landeskliniken, Bristol-Myers Squibb
Squamous Cell Carcinoma of the Skin
12/26
12/27

Download Options